Traders should be aware that this shelf registration makes immediate, dilutive share sales highly likely. Monitor for filings of a prospectus supplement, which will trigger the start of the ATM offering. The stock price is likely to face downward pressure as sales begin.
Price Chart
Executive Summary
Cue Biopharma (CUE) has filed an S-3 shelf registration, enabling it to raise up to $300 million through various securities offerings, including a specific $12.67 million at-the-market (ATM) offering with Jefferies. The company, with a market cap of $28 million and only $27.1 million in cash, faces substantial doubt about its ability to continue as a going concern and is using this filing as a critical tool to secure immediate capital.
Key Financial Metrics
Key Facts
- Cue Biopharma filed an S-3 shelf registration to raise up to $300 million through debt, common stock, preferred stock, and other securities.
- A specific $12.67 million ATM offering with Jefferies is included in this shelf, allowing for immediate, opportunistic sales of common stock.
- The company has a market cap of $28 million, only $27.1 million in cash, and its auditor has issued a going concern opinion.
- The filing is a clear signal of an urgent need for capital, as the company expects its cash to last only into Q1 2027 and must raise substantial additional funds.
- The offering will be dilutive to existing shareholders, with Jefferies receiving a 3% commission on sales.
Financial Impact
The company can raise up to $300 million, with an immediate $12.67 million available. This represents a significant potential dilution, as the $12.67 million offering is 45% of its $28 million market cap.
Risk Factors
- The company may not be able to raise the full amount, leading to a potential liquidity crisis.
- The continuous sale of shares through the ATM offering will create sustained downward pressure on the stock price.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001193125-26-108656 |
| Document: d87688dex44.htm | 0001193125-26-108656 |
| CONTEXT: 10-Q (2025-11-12) | 0001193125-25-277466 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 11d ago | Insider Cluster | $18.67 $16.71 | ▲ +10.50% | ▲ +9.39% | $18.45 (+1.18%) |
Oct 13, 2026 12d ago | 144 | $18.60 $18.67 | ▲ +0.38% | ▲ +0.09% | $18.45 (−0.81%) |
Oct 8, 2026 18d ago | SC 13G/A | $22.33 $27.66 | ▲ +23.87% | ▲ +23.27% | $18.45 (−17.38%) |
Sep 21, 2026 5w ago | 8-K | $28.27 $30.90 | ▲ +9.30% | ▲ +9.32% | $18.45 (−34.74%) |
Sep 20, 2026 5w ago | Press Release | $28.27 $30.90 | ▲ +9.30% | ▲ +9.32% | $18.45 (−34.74%) |
Aug 21, 2026 9w ago | EFFECT | $23.98 $23.18 | ▲ +3.34% | ▲ +3.04% | $18.45 (+23.06%) |
Aug 17, 2026 9w ago | Insider Cluster | $25.70 $26.28 | ▼ −2.26% | ▼ −2.05% | $18.45 (+28.21%) |
Aug 14, 2026 10w ago | Press Release | $27.64 $25.70 | ▼ −7.02% | ▼ −6.34% | $18.45 (−33.25%) |
Aug 13, 2026 10w ago | 144 | $34.20 $27.64 | ▼ −19.18% | ▼ −18.71% | $18.45 (−46.05%) |
Jul 9, 2026 15w ago | Press Release | $36.78 $30.92 | ▼ −15.93% | ▼ −15.17% | $18.45 (−49.84%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers